ADA CERP is a service of the American Dental Association to assist dental professionals in identifying quality providers of continuing dental education. ADA CERP does not approve or endorse individual courses or instructors, nor does it imply acceptance of credit house by boards of dentistry. Concerns or complaints about a CE provider may be directed to the provider or to ADA CERP at www.ada.org/cerp/
Approved PACE Program Provider. FAGD/MAGD credit. Approval does not imply acceptance by a state or provincial board of dentistry, or AGD endorsement. 1/1/2023 to 12/31/2028. ID # 209722.
Released: Wednesday, February 12, 2020
Expires: Tuesday, February 28, 2023
By Mark Donaldson, BSP, ACPR, PharmD, FASHP, FACHE
Commercial Supporter: GlaxoSmithKline
Oral dryness is a ubiquitous oral health symptom, with up to 50% of the population experiencing this condition. Despite the high prevalence of xerostomia in the overall population, standard treatment guidelines do not exist. Management is usually individualized for the specific patient and should be targeted at the underlying pathophysiology of the disease. Accurately diagnosing xerostomia is critical for patients to receive the best treatment possible. Successful treatment often involves a multimodal approach.
About the Author
Mark Donaldson, BSP, ACPR, PharmD, FASHP, FACHE
Associate Principal, Vizient Pharmacy Advisory Solutions, Irving, Texas; Clinical Professor, School of Pharmacy, University of Montana, Missoula, Montana; Clinical Assistant Professor, School of Dentistry, Oregon Health & Sciences University, Portland, Oregon; Adjunct Professor, Faculty of Dentistry, University of British Columbia, Vancouver, British Columbia; Fellow, American Society of Hospital Pharmacists; Fellow, American College of Healthcare Executives